(426) Clinical Follow-Up Of Patients With Multiple Sclerosis 10 Years After Pde5Is Treatment For Erectile Dysfunction: A Real-Life Cohort Study
Charalampos Thomas,Prof Zisis Kratiras,Michael Samarinas,Dr Georgios Diamantis,Charalampos Konstantinidis
DOI: https://doi.org/10.1093/jsxmed/qdae041.014
2024-06-15
The Journal of Sexual Medicine
Abstract:Objectives Erectile Dysfunction (ED) is very common in patients suffering from Multiple Sclerosis (MS); the prevalence varies from 30% to almost 90%.Our aim was to study the adherence of MS patients to PDE5Is, in 10 years period. Methods 119 MS patients suffering from ED that were treated with PDE5Is were evaluated in 2015. Concomitant cardiovascular diseases, hormonal and psychiatric disorders were excluded. Efficacy was evaluated with IIEF5 and SEP2&3 questions. We re-evaluate our data now in order to assess the adherence to PDE5Is, almost 10 years after. Results 10 years after we collected data from 94 patients out of the original 101 responders. From the sildenafil group, 20 out of 36 are still on, 5 on daily tadalafil, 1 on intra-cavernosal injections (ICI), 1 died, 3 were lost from follow up, 1 underwent a 3-piece inflatable penile prosthesis insertion, 2 stopped due to lack of sexual partner and 3 stopped due to MS progression. From the vardenafil group, 5/15 are still on, 2 on sildenafil, 2 on daily tadalafil, 1 on ICC, 3 without partner and 2 stopped due to progression. From the avanafil group, 4/8 responders are still on, 1 ion sildenafil, 1 on daily tadalafil, 1 on ICC and 1 stopped to progression. From the on demand tadalafil group, 7/18 are still on, 5 on daily tadalafil, 1 on sildenafil, 2 were lost from follow up, 1 on ICC, 1 without partner and 1 stopped due to progression. From daily tadalafil group, 10/24 are still on, 1 is dead, 1 on ICC, 6 on sildenafil on, 1 underwent penile prosthesis, 2 without partner, 3 stopped due to progression. Conclusions After almost 10 years of follow up, the majority of our MS patients remained on PDE5 inhibitors, either the one prescribed initially or a different one. The medication dropout rate, in our cohort, is approximately 24%, while disease progression and lack of sexual partner were the major reasons for withdrawal. Conflicts of Interest None.
urology & nephrology